Home / Intelligence / Case Studies / Biosimilar Differentiation Strategy
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
Geographic Scope: 
Client Situation:
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity’s Solution
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.
Deliverables
- Catalogue of value-added services and contracts offered by the originator biologic across market segments
- Biosimilar defense strategies implemented by the manufacturer of the originator biologic
- Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake
- Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation
- Strategic recommendations to drive differentiation of a biosimilar
Project Outcomes & Impact
Trinity was able to support the client with driving differentiation of a biosimilar through service offerings and contracting, with strategies tailored to market segment.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More